Systemic Dosing of Thymosin Beta 4 before and after Ischemia Does Not Attenuate Global Myocardial Ischemia-Reperfusion Injury in Pigs

Show full item record



Permalink

http://hdl.handle.net/10138/163046

Citation

Stark , C K -J , Tarkia , M , Kentala , R , Malmberg , M , Vahasilta , T , Savo , M , Hynninen , V-V , Helenius , M , Ruohonen , S , Jalkanen , J , Taimen , P , Alastalo , T-P , Saraste , A , Knuuti , J , Savunen , T & Koskenvuo , J 2016 , ' Systemic Dosing of Thymosin Beta 4 before and after Ischemia Does Not Attenuate Global Myocardial Ischemia-Reperfusion Injury in Pigs ' , Frontiers in Pharmacology , vol. 7 , 115 . https://doi.org/10.3389/fphar.2016.00115

Title: Systemic Dosing of Thymosin Beta 4 before and after Ischemia Does Not Attenuate Global Myocardial Ischemia-Reperfusion Injury in Pigs
Author: Stark, Christoffer K. -J.; Tarkia, Miikka; Kentala, Rasmus; Malmberg, Markus; Vahasilta, Tommi; Savo, Matti; Hynninen, Ville-Veikko; Helenius, Mikko; Ruohonen, Saku; Jalkanen, Juho; Taimen, Pekka; Alastalo, Tero-Pekka; Saraste, Antti; Knuuti, Juhani; Savunen, Timo; Koskenvuo, Juha
Contributor: University of Helsinki, Turku University Hospital
University of Helsinki, Lastentautien yksikkö
University of Helsinki, Clinicum
Date: 2016-05-03
Language: eng
Number of pages: 10
Belongs to series: Frontiers in Pharmacology
ISSN: 1663-9812
URI: http://hdl.handle.net/10138/163046
Abstract: The use of cardiopulmonary bypass (CPB) and aortic cross-clamping causes myocardial ischemia-reperfusion injury (I-RI) and can lead to reduced postoperative cardiac function. We investigated whether this injury could be attenuated by thymosin beta 4 (TB4), a peptide which has showed cardioprotective effects. Pigs received either TB4 or vehicle and underwent CPB and aortic cross-clamping for 60 min with cold intermittent blood-cardioplegia and were then followed for 30 h. Myocardial function and blood flow was studied by cardiac magnetic resonance and PET imaging. Tissue and plasma samples were analyzed to determine the amount of cardiomyocyte necrosis and apoptosis as well as pharmacokinetics of the peptide. In vitro studies were performed to assess its influence on blood coagulation and vasomotor tone. Serum levels of the peptide were increased after administration compared to control samples. TB4 did not decrease the amount of cell death. Cardiac function and global myocardial blood flow was similar between the study groups. At high doses a vasoconstrictor effect on mesentery arteries and a vasodilator effect on coronary arteries was observed and blood clot firmness was reduced when tested in the presence of an antiplatelet agent. Despite promising results in previous trials the cardioprotective effect of TB4 was not demonstrated in this model for global myocardial I-RI.
Subject: thymosin beta 4
cardiopulmonary bypass
ischemia-reperfusion injury
cardioprotection
coagulation
vasoconstriction
VASCULAR SMOOTH-MUSCLE
INTEGRIN-LINKED KINASE
CARDIAC-SURGERY
CARDIOMYOCYTE APOPTOSIS
CLINICAL IMPLICATIONS
CELL-MIGRATION
CARDIOPROTECTION
HEART
FLOW
VASOCONSTRICTION
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Systemic_Dosing_of_Thymosin.pdf 731.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record